About LARALAB
LARALAB, now part of Abbott, has developed heart.ai, the first fully automated cloud-based solution for cardiac interventions and structural heart care. The platform is powered by deep learning AI to provide precise, data-driven insights for procedure planning in cardiovascular interventions and surgery. Heart.ai offers tailored workflows and clinical applications for structural heart interventions including tricuspid valve replacement (TTVR), transcatheter aortic valve replacement (TAVR), and transcatheter mitral valve replacement (TMVR). The platform features the REC (Rapid Eligibility Check) for pre-screening, a 4D DICOM viewer and analysis toolbox, and automated reporting capabilities that transform image data into clinical reports. LARALAB enables healthcare partners to build their own research registries and has been validated in over 20 clinical publications involving more than 1,000 patient datasets. The company serves health systems, cardiac intervention centers, and research institutions focused on structural heart disease. With both FDA 510(k) clearance and CE marking under MDR, the platform supports clinicians in making optimal treatment decisions for patients considered for cardiovascular interventions. LARALAB partners with leading medical institutions on registry studies including TTVR-AHI Registry, CESAR-TR, and MitrAI, advancing the field of AI-assisted cardiac care.
Clinical Focus
Medical conditions and clinical areas addressed by LARALAB.
Who It Serves
Milestones & Awards
Recent Milestones
FDA 510(k) clearance received April 2025; Partnership with LMU Hospital on Generative AI for Cardiac Treatments announced April 2025; Novel use cases presented at NYValves June 2025; FDA performance study results presented at SCAI 2025 in May 2025; Acquired by Abbott
Key Partnerships
Social & Media
Follow on
Company Details
- Headquarters
- Munich, Bavaria, Germany
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.